Catherine Stehman-Breen, Chroma Medicine CEO
March 1, 2023 06:00 AM ESTUpdated 06:38 AM
Financing
Bioregnum
Cell/Gene Tx

A gene edit­ing 3.0 play­er goes deep on cash, fron­tier sci­ence to put pre­ci­sion epi­ge­net­ics to the big test

Is­si Rozen is as deeply em­bed­ded in­to the gene edit­ing field as any­one in the buzzy Cam­bridge, MA biotech hub. As chief busi­ness of­fi­cer and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times